Home › Steatotic Liver Disease › Missouri
Steatotic Liver Disease clinical trials in Missouri
14 studies for Steatotic Liver Disease are looking for participants at sites in Missouri.
Cities in Missouri
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, St Louis
- 89bio Clinical Study Site, St Louis
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, St Louis
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Oct 5, 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07701993A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Washington University School of Medicine, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- AMR Clinical, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Columbia
- Akero Clinical Study Site, Kansas City
- Akero Clinical Study Site, St Louis
- and 1 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
- GSK Investigational Site, St Louis
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Gastrointestinal Associates, Columbia
- Gateway GI Research, LLC, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
- University of Missouri School of Medicine, Columbia
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 6, 2026 · NCT06571474Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
- University of Missouri School of Medicine, Columbia
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 6, 2026 · NCT06335771A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Kansas City
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Kansas City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- Harry S. Truman Memorial, Columbia, MO, Columbia
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Feb 19, 2026 · NCT05526144From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.